MF
KALV

Magnetar Financial’s KalVista Pharmaceuticals KALV Stock Holding History

Magnetar Financial’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,938
Closed -$177K – 1273
2025
Q4 		$177K Sell
10,938
-15,986
-59% -$212K ﹤0.01% 814
2025
Q3 		$328K Buy
+26,924
New +$372K ﹤0.01% 686

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Magnetar Financial's KALV Position: Q1 2026 in Review

Magnetar Financial sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 10,938 shares — an estimated $177K sold.

Magnetar Financial first reported a position in KALV in Q3 2025 and held it in 2 quarters. The position peaked at $328K in Q3 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Magnetar Financial reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Magnetar Financial sold 10,938 KalVista Pharmaceuticals shares in Q1 2026, an estimated $177K.
  • Magnetar Financial first reported a position in KalVista Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Magnetar Financial's KalVista Pharmaceuticals position peaked at $328K in Q3 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Magnetar Financial's 13F filing for Q1 2026, filed 13 May 2026.